1
|
Sun Z, Zang L, Cheng Y, Qin L. Cancer Exosome Loaded with Paclitaxel for Targeted Lung Cancer Therapy. J BIOMATER TISS ENG 2023. [DOI: 10.1166/jbt.2023.3222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Lung cancer is a serious issue to threat the health of human and the treatment using currently available chemotherapy drug, such as paclitaxel (PTX) is significantly impaired by the poor solubility and targetability. In this study, we used the cancer exosome (CE) derived from lung cancer
cell line A549 to load PTX (CE/PTX) and construct a drug delivery system (DDS) for the treatment of A549 tumor in a mice mode. The DDS realized better inhibition on both A549 cells and tumors as compared to commercial PTX formulation (Taxol). Therefore, we believe this strategy can be applied
to clinical trials for better cancer treatment.
Collapse
Affiliation(s)
- Zhengui Sun
- Department of Respiratory and Critical Care Medicine, Yijishan Hospital, Wannan Medical College, Wuhu, Anhui, 241001, China
| | - Leilei Zang
- Department of Respiratory and Critical Care Medicine, Yijishan Hospital, Wannan Medical College, Wuhu, Anhui, 241001, China
| | - Yusheng Cheng
- Department of Respiratory and Critical Care Medicine, Yijishan Hospital, Wannan Medical College, Wuhu, Anhui, 241001, China
| | - Lilong Qin
- Department of Respiratory and Critical Care Medicine, Yijishan Hospital, Wannan Medical College, Wuhu, Anhui, 241001, China
| |
Collapse
|
2
|
Ling B, Zhang Z, Xiang Z, Cai Y, Zhang X, Wu J. Advances in the application of proteomics in lung cancer. Front Oncol 2022; 12:993781. [PMID: 36237335 PMCID: PMC9552298 DOI: 10.3389/fonc.2022.993781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2022] [Accepted: 08/29/2022] [Indexed: 11/13/2022] Open
Abstract
Although the incidence and mortality of lung cancer have decreased significantly in the past decade, it is still one of the leading causes of death, which greatly impairs people’s life and health. Proteomics is an emerging technology that involves the application of techniques for identifying and quantifying the overall proteins in cells, tissues and organisms, and can be combined with genomics, transcriptomics to form a multi-omics research model. By comparing the content of proteins between normal and tumor tissues, proteomics can be applied to different clinical aspects like diagnosis, treatment, and prognosis, especially the exploration of disease biomarkers and therapeutic targets. The applications of proteomics have promoted the research on lung cancer. To figure out potential applications of proteomics associated with lung cancer, we summarized the role of proteomics in studies about tumorigenesis, diagnosis, prognosis, treatment and resistance of lung cancer in this review, which will provide guidance for more rational application of proteomics and potential therapeutic strategies of lung cancer.
Collapse
Affiliation(s)
- Bai Ling
- Department of Pharmacy, The Yancheng Clinical College of Xuzhou Medical University, The First people’s Hospital of Yancheng, Yancheng, China
| | - Zhengyu Zhang
- Nanjing Medical University School of Medicine, Nanjing, China
| | - Ze Xiang
- Zhejiang University School of Medicine, Hangzhou, China
| | - Yiqi Cai
- Zhejiang University School of Medicine, Hangzhou, China
| | - Xinyue Zhang
- Stomatology Hospital, School of stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, China
| | - Jian Wu
- Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China
- *Correspondence: Jian Wu,
| |
Collapse
|
3
|
Zhang W, Chen Y, Wang B, Feng X, Zhang L, Liu S. Facile Preparation of Paclitaxel Nano-Suspensions to Treat Lung Cancer. J BIOMATER TISS ENG 2022. [DOI: 10.1166/jbt.2022.2940] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Lung cancer is a worldwide issue which account for the death of thousands every year. Paclitaxel (PTX) as the first line chemotherapy drug to treat lung cancer, its clinical applications is largely limited by its poor solubility. The facile preparation of pharmaceutical formulations
to increase the solubility as well as targetability of PTX is of vital importance in lung cancer treatment. Herein, we introduced a facile method to prepare PTX nano-suspensions (NSs), which have high drug loading as well as well-dispersed particle size. The in vitro cell experiments
revealed its capability to enhance the drug accumulation in A549 cells than free PTX. Moreover, in vivo animal assay suggested its better tumor accumulation and antitumor efficacy than PTX injection (Taxol).
Collapse
Affiliation(s)
- Wei Zhang
- Department of Respiratory and Critical Care Medicine, Huzhou Central Hospital of Zhejiang Province, 1558 Sanhuan North Road, Wuxing District, Huzhou City, 313099, Zhejiang Province, China
| | - Yi Chen
- Department of Respiratory and Critical Care Medicine, Huzhou Central Hospital of Zhejiang Province, 1558 Sanhuan North Road, Wuxing District, Huzhou City, 313099, Zhejiang Province, China
| | - Bin Wang
- Department of Respiratory and Critical Care Medicine, Huzhou Central Hospital of Zhejiang Province, 1558 Sanhuan North Road, Wuxing District, Huzhou City, 313099, Zhejiang Province, China
| | - Xueren Feng
- Department of Respiratory and Critical Care Medicine, Huzhou Central Hospital of Zhejiang Province, 1558 Sanhuan North Road, Wuxing District, Huzhou City, 313099, Zhejiang Province, China
| | - Lijuan Zhang
- Department of Respiratory and Critical Care Medicine, Huzhou Central Hospital of Zhejiang Province, 1558 Sanhuan North Road, Wuxing District, Huzhou City, 313099, Zhejiang Province, China
| | - Shunlin Liu
- Department of Respiratory and Critical Care Medicine, Huzhou Central Hospital of Zhejiang Province, 1558 Sanhuan North Road, Wuxing District, Huzhou City, 313099, Zhejiang Province, China
| |
Collapse
|
4
|
Huang M, Zeng L, Zhu R, Chen G, Wu H, Fan B, Liu C, Guo B, Zhong H. Hyaluronic Acid Stabilized Doxorubicin Nano-Precipitations for Osteosarcoma Treatment. J BIOMATER TISS ENG 2022. [DOI: 10.1166/jbt.2022.2935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Doxorubicin (Dox) is a wide-spectrum drug to treat different kinds of cancers. However, in clinical practice, Dox usually showed untargeted distributions to the other organs, which can cause serious side effects, such as cardiotoxity. Herein, the formulation of Dox into nanoparticles
is critical to enhance its distribution to tumors. Herein, we used polysaccharide, hyaluronic acid, to stabilize the Dox to form nano-precipitations (PD NPs) for the therapy of osteosarcoma. The PD NPs showed enhanced drug accumulation to tumor cells and realized better anticancer effects
than free drugs.
Collapse
Affiliation(s)
- Mouzhang Huang
- Department of Orthopedic Surgery, Ganzhou People’s Hospital (The Affitiated Ganzhou Hospital of Nanchang University), Ganzhou, Jiangxi 341000, China
| | - Limei Zeng
- Gannan Medical University, Ganzhou, Jiangxi 341000, China
| | - Rongping Zhu
- Department of Orthopedic Surgery, Ganzhou People’s Hospital (The Affitiated Ganzhou Hospital of Nanchang University), Ganzhou, Jiangxi 341000, China
| | - Gongqun Chen
- Department of Orthopedic Surgery, Ganzhou People’s Hospital (The Affitiated Ganzhou Hospital of Nanchang University), Ganzhou, Jiangxi 341000, China
| | - Haijian Wu
- Department of Orthopedic Surgery, Ganzhou People’s Hospital (The Affitiated Ganzhou Hospital of Nanchang University), Ganzhou, Jiangxi 341000, China
| | - Bin Fan
- Department of Orthopedic Surgery, Ganzhou People’s Hospital (The Affitiated Ganzhou Hospital of Nanchang University), Ganzhou, Jiangxi 341000, China
| | - Changtie Liu
- Department of Orthopedic Surgery, Ganzhou People’s Hospital (The Affitiated Ganzhou Hospital of Nanchang University), Ganzhou, Jiangxi 341000, China
| | - Bowen Guo
- Department of Orthopedic Surgery, Ganzhou People’s Hospital (The Affitiated Ganzhou Hospital of Nanchang University), Ganzhou, Jiangxi 341000, China
| | - Hongfa Zhong
- Department of Orthopedic Surgery, Ganzhou People’s Hospital (The Affitiated Ganzhou Hospital of Nanchang University), Ganzhou, Jiangxi 341000, China
| |
Collapse
|
5
|
Peralta-Arrieta I, Trejo-Villegas OA, Armas-López L, Ceja-Rangel HA, Ordóñez-Luna MDC, Pineda-Villegas P, González-López MA, Ortiz-Quintero B, Mendoza-Milla C, Zatarain-Barrón ZL, Arrieta O, Zúñiga J, Ávila-Moreno F. Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer. Eur J Cancer 2021; 160:189-205. [PMID: 34844838 DOI: 10.1016/j.ejca.2021.10.032] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 10/26/2021] [Indexed: 01/22/2023]
Abstract
BACKGROUND Mesenchyme homeobox-2 (MEOX2)-mediated regulation of glioma-associated oncogene-1 (GLI1) has been associated with poor overall survival, conferring chemoresistance in lung cancer. However, the role of MEOX2/GLI1 in resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)-based therapy remains unexplored in human lung cancer. METHODS Functional assays using genetic silencing strategy by short hairpin RNAs, as well as cytotoxic (tetrazolium dye MTT) and clonogenic assays, were performed to evaluate MEOX2/GLI1-induced malignancy capacity in lung cancer cells. Further analysis performed includes western blot, qPCR and ChIP-qPCR assays to identify whether MEOX2/GLI1 promote EGFR/AKT/ERK activation, as well as EGFR overexpression through epigenetic mechanisms. Finally, preclinical tumour progression in vivo and progression-free disease interval analyses in patients treated with EGFR-TKI were included. RESULTS Overexpressed MEOX2/GLI1 in both EGFR wild-type and EGFR/KRAS-mutated lung cancer cells were detected and involved in the activation/expression of EGFR/AKT/ERK biomarkers. In addition, MEOX2/GLI1 was shown to be involved in the increased proliferation of tumour cells and resistance capacity to cisplatin, EGFR-TKIs (erlotinib and AZD9291 'osimertinib'), AZD8542-SMO, and AZD6244-MEKK1/2. In addition, we identified that MEOX2/GLI1 promote lung tumour cells progression in vivo and are clinically associated with poorer progression-free disease intervals. Finally, both MEOX2 and GLI1 were detected to be epigenetically involved in EGFR expression by reducing both repressive markers polycomb-EZH2 and histone H3K27me3, but, particularly, increasing an activated histone profile H3K27Ac/H3K4me3 at EGFR-gene enhancer-promoter sequences that probably representing a novel EGFR-TKI-based therapy resistance mechanism. CONCLUSION MEOX2/GLI1 promote resistance to cisplatin and EGFR-TKI-based therapy in lung cancer cells, modulating EGFR/AKT/ERK signalling pathway activation, as well as inducing an aberrant epigenetic modulation of the EGFR-gene expression in human lung cancer.
Collapse
Affiliation(s)
- Irlanda Peralta-Arrieta
- Universidad Nacional Autónoma de México (UNAM), Unidad de Investigación en Biomedicina (UBIMED), Facultad de Estudios Superiores (FES) Iztacala, Tlalnepantla de Baz, 54090, Estado de México, Mexico.
| | - Octavio A Trejo-Villegas
- Universidad Nacional Autónoma de México (UNAM), Unidad de Investigación en Biomedicina (UBIMED), Facultad de Estudios Superiores (FES) Iztacala, Tlalnepantla de Baz, 54090, Estado de México, Mexico.
| | - Leonel Armas-López
- Universidad Nacional Autónoma de México (UNAM), Unidad de Investigación en Biomedicina (UBIMED), Facultad de Estudios Superiores (FES) Iztacala, Tlalnepantla de Baz, 54090, Estado de México, Mexico.
| | - Hugo A Ceja-Rangel
- Universidad Nacional Autónoma de México (UNAM), Unidad de Investigación en Biomedicina (UBIMED), Facultad de Estudios Superiores (FES) Iztacala, Tlalnepantla de Baz, 54090, Estado de México, Mexico.
| | - María Del Carmen Ordóñez-Luna
- Universidad Nacional Autónoma de México (UNAM), Unidad de Investigación en Biomedicina (UBIMED), Facultad de Estudios Superiores (FES) Iztacala, Tlalnepantla de Baz, 54090, Estado de México, Mexico.
| | - Priscila Pineda-Villegas
- Universidad Nacional Autónoma de México (UNAM), Unidad de Investigación en Biomedicina (UBIMED), Facultad de Estudios Superiores (FES) Iztacala, Tlalnepantla de Baz, 54090, Estado de México, Mexico.
| | - Marco A González-López
- Unidad Funcional de Oncología Torácica, Instituto Nacional de Cancerología (INCan), Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, 14080, Ciudad de México, Mexico.
| | - Blanca Ortiz-Quintero
- Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Calz de Tlalpan, 14080, Ciudad de México, Mexico.
| | - Criselda Mendoza-Milla
- Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Calz de Tlalpan, 14080, Ciudad de México, Mexico.
| | - Zyanya L Zatarain-Barrón
- Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Campus Ciudad de México, Mexico.
| | - Oscar Arrieta
- Unidad Funcional de Oncología Torácica, Instituto Nacional de Cancerología (INCan), Av. San Fernando 22, Belisario Domínguez Secc 16, Tlalpan, 14080, Ciudad de México, Mexico.
| | - Joaquín Zúñiga
- Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Calz de Tlalpan, 14080, Ciudad de México, Mexico; Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Campus Ciudad de México, Mexico.
| | - Federico Ávila-Moreno
- Universidad Nacional Autónoma de México (UNAM), Unidad de Investigación en Biomedicina (UBIMED), Facultad de Estudios Superiores (FES) Iztacala, Tlalnepantla de Baz, 54090, Estado de México, Mexico; Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Calz de Tlalpan, 14080, Ciudad de México, Mexico.
| |
Collapse
|
6
|
Narasimhan M, Khamkar V, Tilwani S, Dalal SN, Shetty D, Subramanian PG, Gupta S, Govekar R. Atypical activation of signaling downstream of inactivated Bcr-Abl mediates chemoresistance in chronic myeloid leukemia. J Cell Commun Signal 2021; 16:207-222. [PMID: 34596797 DOI: 10.1007/s12079-021-00647-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Accepted: 09/20/2021] [Indexed: 11/28/2022] Open
Abstract
Chronic myeloid leukemia (CML) epitomises successful targeted therapy, where inhibition of tyrosine kinase activity of oncoprotein Bcr-Abl1 by imatinib, induces remission in 86% patients in initial chronic phase (CP). However, in acute phase of blast crisis, 80% patients show resistance, 40% among them despite inhibition of Bcr-Abl1 activity. This implies activation of either Bcr-Abl1- independent signalling pathways or restoration of signalling downstream of inactive Bcr-Abl1. In the present study, mass spectrometry and subsequent in silico pathway analysis of differentiators in resistant CML-CP cells identified key differentiators, 14-3-3ε and p38 MAPK, which belong to Bcr-Abl1 pathway. Their levels and activity respectively, indicated active Bcr-Abl1 pathway in CML-BC resistant cells, though Bcr-Abl1 is inhibited by imatinib. Further, contribution of these components to resistance was demonstrated by inhibition of Bcr-Abl1 down-stream signalling by knocking-out of 14-3-3ε and inhibition of p38 MAPK activity. The observations merit clinical validation to explore their translational potential.
Collapse
Affiliation(s)
- Mythreyi Narasimhan
- Rukmini Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.,Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai, 400094, India
| | - Vaishnavi Khamkar
- Rukmini Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India
| | - Sarika Tilwani
- Sorab Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.,Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai, 400094, India
| | - Sorab N Dalal
- Sorab Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.,Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai, 400094, India
| | - Dhanlaxmi Shetty
- Department of Cancer Cytogenetics, , ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India
| | - P G Subramanian
- Hematopathology Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.,Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai, 400094, India
| | - Sanjay Gupta
- Gupta Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.,Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai, 400094, India
| | - Rukmini Govekar
- Rukmini Lab, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India. .,Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai, 400094, India.
| |
Collapse
|
7
|
Lombardi R, Sonego M, Pucci B, Addi L, Iannelli F, Capone F, Alfano L, Roca MS, Milone MR, Moccia T, Costa A, Di Gennaro E, Bruzzese F, Baldassarre G, Budillon A. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer. Mol Oncol 2021; 15:1005-1023. [PMID: 33331136 PMCID: PMC8024727 DOI: 10.1002/1878-0261.12883] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 11/05/2020] [Accepted: 12/14/2020] [Indexed: 12/23/2022] Open
Abstract
Acquired resistance to platinum (Pt)-based therapies is an urgent unmet need in the management of epithelial ovarian cancer (EOC) patients. Here, we characterized by an unbiased proteomics method three isogenic EOC models of acquired Pt resistance (TOV-112D, OVSAHO, and MDAH-2774). Using this approach, we identified several differentially expressed proteins in Pt-resistant (Pt-res) compared to parental cells and the chaperone HSP90 as a central hub of these protein networks. Accordingly, up-regulation of HSP90 was observed in all Pt-res cells and heat-shock protein 90 alpha isoform knockout resensitizes Pt-res cells to cisplatin (CDDP) treatment. Moreover, pharmacological HSP90 inhibition using two different inhibitors [17-(allylamino)-17-demethoxygeldanamycin (17AAG) and ganetespib] synergizes with CDDP in killing Pt-res cells in all tested models. Mechanistically, genetic or pharmacological HSP90 inhibition plus CDDP -induced apoptosis and increased DNA damage, particularly in Pt-res cells. Importantly, the antitumor activities of HSP90 inhibitors (HSP90i) were confirmed both ex vivo in primary cultures derived from Pt-res EOC patients ascites and in vivo in a xenograft model. Collectively, our data suggest an innovative antitumor strategy, based on Pt compounds plus HSP90i, to rechallenge Pt-res EOC patients that might warrant further clinical evaluation.
Collapse
Affiliation(s)
- Rita Lombardi
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Maura Sonego
- Division of Molecular OncologyCentro di Riferimento Oncologico di Aviano (CRO)IRCCSAvianoItaly
| | - Biagio Pucci
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Laura Addi
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Federica Iannelli
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Francesca Capone
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Luigi Alfano
- Cell Biology and Biotherapy UnitIstituto Nazionale Tumori ‐ IRCCS, Fondazione G. PascaleNaplesItaly
| | - Maria Serena Roca
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Maria Rita Milone
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Tania Moccia
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Alice Costa
- Division of Molecular OncologyCentro di Riferimento Oncologico di Aviano (CRO)IRCCSAvianoItaly
- University of TriesteItaly
| | - Elena Di Gennaro
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Francesca Bruzzese
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Gustavo Baldassarre
- Division of Molecular OncologyCentro di Riferimento Oncologico di Aviano (CRO)IRCCSAvianoItaly
| | - Alfredo Budillon
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| |
Collapse
|
8
|
Ashrafizadeh M, Zarrabi A, Hushmandi K, Kalantari M, Mohammadinejad R, Javaheri T, Sethi G. Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance. Int J Mol Sci 2020; 21:E4002. [PMID: 32503307 PMCID: PMC7312011 DOI: 10.3390/ijms21114002] [Citation(s) in RCA: 155] [Impact Index Per Article: 38.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Revised: 05/14/2020] [Accepted: 05/26/2020] [Indexed: 02/08/2023] Open
Abstract
Therapy resistance is a characteristic of cancer cells that significantly reduces the effectiveness of drugs. Despite the popularity of cisplatin (CP) as a chemotherapeutic agent, which is widely used in the treatment of various types of cancer, resistance of cancer cells to CP chemotherapy has been extensively observed. Among various reported mechanism(s), the epithelial-mesenchymal transition (EMT) process can significantly contribute to chemoresistance by converting the motionless epithelial cells into mobile mesenchymal cells and altering cell-cell adhesion as well as the cellular extracellular matrix, leading to invasion of tumor cells. By analyzing the impact of the different molecular pathways such as microRNAs, long non-coding RNAs, nuclear factor-κB (NF-ĸB), phosphoinositide 3-kinase-related protein kinase (PI3K)/Akt, mammalian target rapamycin (mTOR), and Wnt, which play an important role in resistance exhibited to CP therapy, we first give an introduction about the EMT mechanism and its role in drug resistance. We then focus specifically on the molecular pathways involved in drug resistance and the pharmacological strategies that can be used to mitigate this resistance. Overall, we highlight the various targeted signaling pathways that could be considered in future studies to pave the way for the inhibition of EMT-mediated resistance displayed by tumor cells in response to CP exposure.
Collapse
Affiliation(s)
- Milad Ashrafizadeh
- Department of Basic Science, Faculty of Veterinary Medicine, University of Tabriz, Tabriz 5166616471, Iran;
| | - Ali Zarrabi
- Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, Istanbul 34956, Turkey;
- Center of Excellence for Functional Surfaces and Interfaces (EFSUN), Faculty of Engineering and Natural Sciences, Sabanci University, Tuzla, Istanbul 34956, Turkey
| | - Kiavash Hushmandi
- Department of Food Hygiene and Quality Control, Division of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran 1417414418, Iran;
- Kazerun Health Technology Incubator, Shiraz University of Medical Sciences, Shiraz 1433671348, Iran
| | - Mahshad Kalantari
- Department of Genetic Science, Tehran Medical Science Branch, Islamic Azad University, Tehran 19168931813, Iran;
| | - Reza Mohammadinejad
- Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman 1355576169, Iran
| | - Tahereh Javaheri
- Health Informatics Lab, Metropolitan College, Boston University, Boston, MA 02215, USA
| | - Gautam Sethi
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore;
| |
Collapse
|
9
|
Proteomic Technology "Lens" for Epithelial-Mesenchymal Transition Process Identification in Oncology. Anal Cell Pathol (Amst) 2019; 2019:3565970. [PMID: 31781477 PMCID: PMC6855076 DOI: 10.1155/2019/3565970] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2019] [Revised: 08/20/2019] [Accepted: 09/10/2019] [Indexed: 02/08/2023] Open
Abstract
The epithelial-mesenchymal transition (EMT) is a complex transformation process that induces local and distant progression of many malignant tumours. Due to its complex array of proteins that are dynamically over-/underexpressed during this process, proteomic technologies gained their place in the EMT research in the last years. Proteomics has identified new molecular pathways of this process and brought important insights to develop new therapy targets. Various proteomic tools and multiple combinations were developed in this area. Out of the proteomic technology armentarium, mass spectrometry and array technologies are the most used approaches. The main characteristics of the proteomic technology used in this domain are high throughput and detection of minute concentration in small samples. We present herein, using various proteomic technologies, the identification in cancer cell lines and in tumour tissue EMT-related proteins, proteins that are involved in the activation of different cellular pathways. Proteomics has brought besides standard EMT markers (e.g., cell-cell adhesion proteins and transcription factors) other future potential markers for improving diagnosis, monitoring evolution, and developing new therapy targets. Future will increase the proteomic role in clinical investigation and validation of EMT-related biomarkers.
Collapse
|
10
|
Cang S, Liu R, Wang T, Jiang X, Zhang W, Bi K, Li Q. Simultaneous determination of five active alkaloids from Compound Kushen Injection in rat plasma by LC–MS/MS and its application to a comparative pharmacokinetic study in normal and NSCLC nude rats. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1126-1127:121734. [DOI: 10.1016/j.jchromb.2019.121734] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 07/15/2019] [Accepted: 07/24/2019] [Indexed: 02/02/2023]
|